Full-Time

Senior Medical Science Liaison Rare Disease

Posted on 2/26/2025

Acadia Pharmaceuticals

Acadia Pharmaceuticals

501-1,000 employees

Develops treatments for neuro-psychiatric disorders

Compensation Overview

$176k - $220k/yr

+ Discretionary Bonus + Equity Awards

Senior

Boston, MA, USA + 2 more

More locations: New York, NY, USA | New Haven, CT, USA

Candidates must be based in the Northeast region, specifically near New Haven, CT; Boston, MA; or New York, NY.

Category
Healthcare Administration & Support
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Advanced degree (MD, PharmD, PhD) in a scientific discipline or related field
  • 5 years of progressively responsible experience within the pharmaceutical or biotech industry
  • Focus on rare diseases, epilepsy, neurology or psychiatry is strongly preferred
  • Previous MSL experience desired
  • 7 years of progressively responsible experience in the medical, clinical, and/or pharmaceutical field for Sr. Medical Science Liaison
  • 3 years as an MSL for Sr. Medical Science Liaison
Responsibilities
  • Identifies and develops relationships with national and regional medical and scientific thought leaders, patient advocacy groups, and centers of excellence
  • Engages national and regional thought leaders to align interests, discuss research and medical information, and participate in scientific exchange and education
  • Provides research trial site support and investigator-initiated research proposal cultivation and facilitation
  • Develops and maintains scientific, clinical and therapeutic expertise for Acadia’s portfolio
  • Cross-functionally collaborates with regional field leadership partners including Regional Business Leaders (RBL) and Account Business Managers (ABMs)
  • Provides strategic field insights
  • Identifies disease concepts and compound characteristics that can be leveraged into product differentiation
  • Provides appropriate scientific, clinical, and educational support for internal and external clients
  • Represents the company at specific continuing educational events, programs, medical meetings and conventions
  • Supports Commercial operations by participating in Speaker and Sales Representative Training
  • Partners with the internal departments to ensure accurate delivery of medical and scientific information
  • Performs other duties as assigned
Desired Qualifications
  • Knowledge of regulatory, compliance, commercial, and clinical issues affecting the pharmaceutical and managed care industries
  • Knowledge of customer segments and market dynamics
  • Excellent planning and organizational skills
  • Ability to work independently and with cross-functional teams
  • Excellent oral and written communication skills, including presentation and facilitation formats
  • Demonstrated expertise in drug information communication
  • Skilled at negotiating with business partners or management and influencing leaders
  • Highly skilled and proficient with all MS Suites programs, including Outlook, Word, Excel, and PowerPoint
  • Ability to travel up to 75% of time, with primary residence within the territory area
Acadia Pharmaceuticals

Acadia Pharmaceuticals

View

Acadia Pharmaceuticals focuses on developing and providing treatments for patients with serious neurological and psychiatric conditions. The company has created the first FDA-approved medication specifically for managing hallucinations and delusions related to Parkinson's disease psychosis, as well as the first approved treatment for Rett syndrome in the U.S. and Canada. Their products work by targeting the underlying symptoms of these conditions, helping to improve the quality of life for patients. What sets Acadia apart from its competitors is its dedication to addressing rare and complex neuro-psychiatric disorders, with ongoing research aimed at conditions like Prader-Willi syndrome and Alzheimer’s disease psychosis. The goal of Acadia Pharmaceuticals is to enable brighter moments for patients and their families by providing effective solutions for challenging health issues.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Acadia's DAYBUE is now available for treating Rett syndrome in the U.S.
  • The company benefits from increased focus on rare diseases and orphan drug incentives.
  • Successful public offering indicates strong investor confidence and capital for R&D.

What critics are saying

  • Increased competition in CNS disorder treatments, including RNA-based therapies.
  • Class action lawsuit could lead to financial and reputational damage.
  • Potential over-reliance on partnerships like the one with Neuren Pharmaceuticals.

What makes Acadia Pharmaceuticals unique

  • Acadia focuses on CNS disorders with innovative small molecule drugs.
  • The company launched a documentary series to raise awareness for Rett syndrome.
  • Acadia collaborates with Stoke Therapeutics on RNA-based therapies for Rett syndrome.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 0%

2 year growth

↑ 1%
Endpoints News
May 30th, 2025
Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech

Allyson McMillan-Youngblood has left Bristol Myers Squibb to join Acadia Pharmaceuticals as SVP of its rare disease franchise.

ETF Daily News
Mar 27th, 2025
Cibc World Markets Corp Invests $206,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Cibc World Markets Corp invests $206,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Fierce Pharma
Dec 9th, 2024
Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO).

MarketWatch
Nov 26th, 2024
Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711

Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711.

World Pharmaceuticals
Oct 17th, 2024
Acadia gets Health Canada approval for Daybue to treat Rett Syndrome

US-based biopharmaceutical company Acadia Pharmaceuticals has received Health Canada marketing authorisation for Daybue (trofinetide) to treat a rare genetic neurological disorder.

INACTIVE